Φορτώνει......
Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron
As recommended by most recent antiemetic guidelines, the optimal prophylaxis of chemotherapy-induced nausea and vomiting (CINV) requires the combination of 5-HT3 receptor antagonist (RA) with an NK1-RA. Moreover, the major predictors of acute and delayed CINV include: young age, female sex, platinum...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Ther Clin Risk Manag |
|---|---|
| Κύριος συγγραφέας: | |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Dove Medical Press
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4907706/ https://ncbi.nlm.nih.gov/pubmed/27354807 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S89215 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|